Incorporating platelet glycoprotein iib/iiia inhibition in critical pathways: Unstable angina/non-st-segment elevation myocardial infarction
Key result
Platelet glycoprotein IIb/IIIa inhibitors reduce thrombotic events and mortality in acute coronary syndromes, supporting their routine use in critical pathways despite cost constraints.
Population
Patients with acute coronary syndromes undergoing percutaneous coronary intervention and patients with…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support targeted use in high-risk ACS; leaves open net benefit versus modern P2Y12 inhibitors.
Structured PICO
P
Population
Patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI) and patients with unstable angina/non-ST-segment elevation myocardial infarction (MI)
I
Intervention
Platelet glycoprotein (GP) IIb/IIIa inhibitors
The benefits of GP IIb/IIIa receptor inhibition in reducing thrombotic events and mortality suggest the utility of adopting their routine use in critical pathways for unstable angina/NSTEMI and PCI, potentially targeted based on patient risk assessment due to cost constraints.
Limitations
- Cost constraints may limit routine use, warranting targeted treatment based on patient risk assessment.
Cite This Study
Christopher P. Cannon (1999) conducted a review in Unstable angina/non-ST-segment elevation myocardial infarction. Platelet glycoprotein (GP) IIb/IIIa inhibitors was evaluated. Platelet glycoprotein IIb/IIIa inhibitors reduce thrombotic events and mortality in acute coronary syndromes, supporting their routine use in critical pathways despite cost constraints.